All Stories

  1. Yellow fever vaccine propagation in primary human hepatocytes triggers antiviral and cytolytic responses
  2. From Discovery to Therapy: The Role of HSPB1 in HBV Persistence
  3. Seroprevalence of segmented flavi-like Alongshan virus in horses
  4. From zoonotic spillover to endemicity: the broad determinants of human coronavirus tropism
  5. Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants
  6. Adapted hepatitis C virus clone infects innate immunity-deficient mouse hepatocytes with minimal human HCV entry factors
  7. Differential efficacy of first licensed western vaccines protecting without immunopathogenesis Wuhan-1-challenged hamsters from severe COVID-19
  8. The glutamate receptor antagonist ifenprodil inhibits hepatitis E virus infection
  9. MicroRNAs modulate SARS‐CoV‐2 infection of primary human hepatocytes by regulating the entry factors ACE2 and TMPRSS2
  10. Inactivation of yellow fever virus by WHO-recommended hand rub formulations and surface disinfectants
  11. Host determinants and responses underlying SARS-CoV-2 liver tropism
  12. TMPRSS2-mediated SARS-CoV-2 uptake boosts innate immune activation, enhances cytopathology, and drives convergent virus evolution
  13. Targeting cellular cathepsins inhibits hepatitis E virus entry
  14. Unraveling the dynamics of hepatitis C virus adaptive mutations and their impact on antiviral responses in primary human hepatocytes
  15. Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets
  16. Spatiotemporal analysis of SARS-CoV-2 infection reveals an expansive wave of monocyte-derived macrophages associated with vascular damage and virus clearance in hamster lungs
  17. Productive infection of primary human hepatocytes with SARS-CoV-2 induces antiviral and proinflammatory responses
  18. Mouse Liver-Expressed Shiftless Is an Evolutionarily Conserved Antiviral Effector Restricting Human and Murine Hepaciviruses
  19. Spatiotemporal analysis of SARS-CoV-2 infection reveals an expansive wave of monocyte-derived macrophages associated with vascular damage and virus clearance in hamster lungs
  20. SARS-CoV-2 entry route impacts a range of downstream viral and cellular processes
  21. Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization
  22. The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection
  23. Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance
  24. In contrast to TH2-biased approaches, TH1 COVID-19 vaccines protect Syrian hamsters from severe disease in the absence of dexamethasone-treatable vaccine-associated enhanced respiratory pathology
  25. Generation of hiPSC-derived low threshold mechanoreceptors containing axonal termini resembling bulbous sensory nerve endings and expressing Piezo1 and Piezo2
  26. Strategies to Inhibit Hepatitis B Virus at the Transcript Level
  27. Initial Hepatitis C Virus Infection of Adult Hepatocytes Triggers a Temporally Structured Transcriptional Program Containing Diverse Pro- and Antiviral Elements
  28. Single-cell analysis of arthritogenic alphavirus-infected human synovial fibroblasts links low abundance of viral RNA to induction of innate immunity and arthralgia-associated gene expression
  29. Liver-expressed Cd302 and Cr1l limit hepatitis C virus cross-species transmission to mice
  30. C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle
  31. Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus
  32. Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus
  33. Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver
  34. A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
  35. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants
  36. Hepatitis C Virus
  37. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies
  38. Molecular characteristics and successful management of a respiratory syncytial virus outbreak among pediatric patients with hemato-oncological disease
  39. Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions
  40. Immune protection against reinfection with nonprimate hepacivirus
  41. Exacerbation of hepatitis E virus infection during anti-TNFα treatment
  42. Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy
  43. Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission
  44. Mutagenic Effects of Ribavirin on Hepatitis E Virus—Viral Extinction versus Selection of Fitness-Enhancing Mutations
  45. Vertical transmission of hepatitis C virus-like non-primate hepacivirus in horses
  46. Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection
  47. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
  48. Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7
  49. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance
  50. Flunarizine prevents hepatitis C virus membrane fusion in a genotype‐dependent manner by targeting the potential fusion peptide within E1
  51. Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice
  52. Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design
  53. Clinical course of infection and viral tissue tropism of hepatitis C virus-like nonprimate hepaciviruses in horses
  54. Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region
  55. Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles
  56. Natural reservoirs for homologs of hepatitis C virus
  57. Recombinant Human L-Ficolin Directly Neutralizes Hepatitis C Virus Entry
  58. Use of short tandem repeat fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies
  59. Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells
  60. Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution
  61. Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells
  62. Characterization of Hepatitis C Virus Intra- and Intergenotypic Chimeras Reveals a Role of the Glycoproteins in Virus Envelopment
  63. An Alpaca Nanobody Inhibits Hepatitis C Virus Entry And Cell-To-Cell Transmission
  64. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells
  65. Hepatitis C Virus Envelope Glycoprotein Fitness Defines Virus Population Composition following Transmission to a New Host
  66. Naturally Occurring Antibodies That Recognize Linear Epitopes in the Amino Terminus of the Hepatitis C Virus E2 Protein Confer Noninterfering, Additive Neutralization
  67. Intercompartmental Recombination of HIV-1 Contributes to env Intrahost Diversity and Modulates Viral Tropism and Sensitivity to Entry Inhibitors
  68. Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype
  69. Acute Hepatitis C Virus Infection: A Dynamic—and Challenging—Concept
  70. A case of hepatitis C virus transmission acquired through sharing a haemodialysis machine
  71. Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis
  72. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors
  73. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33
  74. Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes
  75. Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding
  76. Non-Macrophage-Tropic Human Immunodeficiency Virus Type 1 R5 Envelopes Predominate in Blood, Lymph Nodes, and Semen: Implications for Transmission and Pathogenesis
  77. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33
  78. Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection